Stocktoria
Lyell Immunopharma, Inc. LYEL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-06-17
Lyell Immunopharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $36,000 | $61,000 | $130,000 | $84.7M | $10.7M |
| R&D expense | — | — | $182.9M | $159.2M | $138.7M |
| Operating income | -$269.4M | -$358.8M | -$247.0M | -$187.1M | -$214.8M |
| Income tax | $0 | — | — | — | — |
| Net income | -$274.4M | -$343.0M | -$234.6M | -$183.1M | -$250.2M |
| EPS (diluted) | $-16.06 | $-26.23 | $-18.70 | $-0.74 | $-1.84 |
| Operating cash flow | -$150.0M | -$162.4M | -$163.7M | -$169.6M | -$126.2M |
| Free cash flow | -$150.8M | -$162.9M | -$166.4M | -$193.8M | -$191.8M |
| Cash & equivalents | $60.2M | $105.6M | $145.6M | $123.6M | $293.8M |
| Total assets | $340.1M | $490.9M | $750.0M | $937.6M | $1.1B |
| Total liabilities | $91.8M | $108.0M | $95.1M | $104.3M | $197.6M |
| Shareholders' equity | $248.2M | $382.8M | $655.0M | $833.3M | $929.8M |
Source: SEC EDGAR filings · CIK 0001806952 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.